Arizona State University

Farzaneh Moghadam

Mo Reza Ebrahimkhani

Samira Kiani

Karen Anderson

Sri Krishna

Radwa Ewaisha

Shayesteh Roshdi Ferdosi

Swechchha Pradhan

Provided herein are methods and compositions for reducing an undesirable T cell immune response in human patients prior to and/or during gene therapy using CRISPR/Cas9-based genetic modulation.

Modulating human Cas9-specific host immune response

Provided herein are CRISPR-based synthetic repression systems as well as methods and compositions using the synthetic repression systems to treat septicemia, an adverse immune response in a subject and Waldenström macroglobulinemia.

Synthetic immunomodulation with a CRISPR super-repressor in vivo

Aspects of the disclosure relate to synthetic regulatory systems composed of a multifunctional Cas nuclease, at least two guide RNAs (gRNAs) configured to target distinct nucleotide sequences, and a multilayered regulatory control element comprising ribozyme-based safety switches providing spatial and temporal control over the synthetic circuit in vivo.

CRISPR logic circuits for safer and controllable gene therapies

Growing community of inventors

Tempe, AZ, United States of America

Farzaneh Moghadam